SCHEMBL5670409

SCHEMBL5670409

c1nc(NC2CCNCC2)c2nc[nH]c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 2/20 0.48
AURKA O14965 1/20 0.48
LMNA P02545 5/20 0.47
HTT P42858 3/20 0.47
PAK1 Q13153 1/20 0.47
HSD17B10 Q99714 5/20 0.46
PKM P14618 2/20 0.46
HPGDS O60760 2/20 0.43
CYP1A2 P05177 9/20 0.42
CYP2D6 P10635 5/20 0.42
CYP3A4 P08684 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
USP2 O75604 2/20 0.42
ALDH1A1 P00352 2/20 0.42
ALOX15 P16050 1/20 0.42
HIF1A Q16665 1/20 0.42
NFKB1 P19838 1/20 0.41
ADORA1 P30542 1/20 0.41
THPO P40225 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1748687 0.98 RPS6KB1 (0.47) RPS6KB1AURKALMNAHTTPAK1
SCHEMBL797545 0.90 LMNA (0.51) LMNAHTTPAK1HSD17B10PKM
SCHEMBL30473749 0.90 LMNA (0.51) LMNAHTTPAK1HSD17B10PKM
SCHEMBL5452621 0.87 LMNA (0.60) LMNAHTTPAK1HSD17B10PKM
SCHEMBL9205078 0.87 LMNA (0.56) LMNAHTTPAK1HSD17B10PKM
SCHEMBL797230 0.86 LMNA (0.61) LMNAHTTPAK1HSD17B10PKM
SCHEMBL5458071 0.86 LMNA (0.61) LMNAHTTPAK1HSD17B10PKM
SCHEMBL29684584 0.78 IKBKB (0.39) RPS6KB1AURKACYP1A2CYP2D6MEN1
SCHEMBL6643407 0.76 GBA1 (0.39) LMNAHTTPAK1HPGDS
SCHEMBL5264885 0.76 ULK1 (0.41) RPS6KB1AURKAHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101489559-B Purine and deazapurine derivatives as pharmaceutical compounds ASTEX THERAPEUTICS LTD 2012-08-15 CN disclosed
US-7968568-B2 [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus HOFFMANN-LA ROCHE INC. (US) 2011-06-28 US disclosed
US-7968568-B2 [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus HOFFMANN-LA ROCHE INC. (US) 2011-06-28 US disclosed
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives CHRIST ANDREAS D 2010-03-18 US disclosed
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives CHRIST ANDREAS D 2010-03-18 US disclosed
US-7674804-B2 Pyrimidine and quinazoline derivatives as SST5 modulators HOFFMANN-LA ROCHE INC. (US) 2010-03-09 US disclosed
US-7674804-B2 Pyrimidine and quinazoline derivatives as SST5 modulators HOFFMANN-LA ROCHE INC. (US) 2010-03-09 US disclosed
CN-101489559-A Purine and deazapurine derivatives as pharmaceutical compounds ASTEX THERAPEUTICS LTD (GB) 2009-07-22 CN disclosed
CN-101484173-A Pharmaceutical combinations of pk inhibitors and other active agents ASTEX THERAPEUTICS LTD (GB) 2009-07-15 CN disclosed
US-20080045550-A1 Pyrimidine and quinazoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 US disclosed
US-20080045550-A1 Pyrimidine and quinazoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 US disclosed
WO-2006046024-A1 ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives SSTR5, SSTR3, NPY5R RPS6KB1 1451/4885AURKA 3568/4885LMNA 3799/4885
US-20080045550-A1 Pyrimidine and quinazoline derivatives SSTR5, SSTR3, NPY5R RPS6KB1 1451/4885AURKA 3568/4885LMNA 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.